EGFR inhibitory monoclonal antibodies and EGFR tyrosine kinase inhibitors have distinct effects on the keratinocyte innate immune response

Abstract

Epidermal growth factor receptor inhibitors (EGFRIs) are a well-established targeted therapy for several cancers. Two categories of EGFRIs are known, EGFR tyrosine kinase inhibitors (EGFR-TKIs) and EGFR monoclonal antibodies (EGFR mAbs). These EGFRIs frequently cause cutaneous adverse effects, such as papulo-pustular eruptions, xerosis and chronic paronychia.

This article is protected by copyright. All rights reserved.

http://ift.tt/2mrNWIz